Nanoparticle Drug Delivery for HIV CNS Reservoirs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment regimens fail to effectively target viral reservoirs in the central nervous system and brain, and pose risks to the fetus due to placental barrier crossing, necessitating novel compositions and methods for treating HIV infection that do not cross the placental barrier.
Innovation Solution
Development of nanoparticles comprising a mitochondrial targeting moiety, an anti-HIV therapeutic agent, and/or an anti-oxidant or anti-inflammatory agent, specifically designed to cross the blood-brain barrier while avoiding the placental barrier, using a combination of antiretroviral drugs, Coenzyme Q10, and prodrugs of aspirin or prednisone, to reduce HIV levels in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If small molecule based lipophilic drugs are used to treat HIV, then they can cross the placental barrier and reach the fetus, but this causes harm to the fetus
Solution Approach 1:
The patent uses a nanoparticle as an intermediary delivery vehicle that selectively transports antiretroviral drugs across the blood-brain barrier while being blocked by the placental barrier. The nanoparticle comprises a lipid bilayer membrane with specific properties that enable BBB penetration but prevent placental crossing, thereby mediating selective drug delivery to the CNS without fetal exposure
Solution Approach 2:
The invention creates different delivery properties for different biological barriers by designing nanoparticles with specific lipid composition and size characteristics. The nanoparticle exhibits locally adaptive behavior: it crosses the BBB effectively but is retained by the placenta, achieving spatially differentiated drug distribution that protects the fetus while treating the mother's CNS HIV reservoirs
2Quantity of substance
If antiretroviral drugs are administered to treat HIV, then viral levels in blood can be reduced to undetectable levels, but viral reservoirs in the central nervous system persist
Solution Approach 1:
The patent segments the drug delivery system into two distinct components: a standard of care antiretroviral drug for systemic HIV suppression, and a nanoparticle formulation specifically designed for CNS reservoir targeting. This segmentation allows the drug to perform different functions in different compartments - maintaining undetectable blood viral levels while simultaneously attacking hidden CNS reservoirs through selective nanoparticle-mediated brain delivery
Solution Approach 2:
The nanoparticle acts as a mediator that bridges the gap between systemic drug administration and CNS reservoir access. It carries the antiretroviral drug across the blood-brain barrier, enabling the drug to reach and eliminate viral reservoirs in the central nervous system that would otherwise be inaccessible to conventional therapy
3Quantity of substance
If drugs are delivered into the brain to treat HIV reservoirs, then CNS HIV levels can be reduced, but the blood-brain barrier selectively prevents adequate drug delivery
Solution Approach 1:
The patent changes the physical and chemical parameters of the drug delivery system by encapsulating the antiretroviral drug in nanoparticles with specific properties (lipid bilayer composition, particle size, surface charge). These parameter changes enable the drug to overcome the blood-brain barrier's selective permeability, transforming it from an impermeable obstacle to a crossable interface
Solution Approach 2:
The nanoparticle serves as an intermediary carrier that facilitates drug transport across the blood-brain barrier. It interacts with the barrier's transport mechanisms to enable selective penetration, allowing adequate drug concentrations to reach the brain while the barrier remains intact and continues to protect other compartments
Data Source
AI summary
The present disclosure relates to nanoparticle compositions and uses thereof for treating or preventing HIV infection.